Favorable Long-Term Functional Outcomes and Safety of Auditory Brainstem Implants in Nontumor Patients

Auditory brainstem implants (ABIs) were designed to restore hearing in deaf patients with auditory tumors or those unable to receive cochlear implants. Although ABIs may help some patients, their long-term outcomes have been rarely studied.

To assess the long-term benefits and safety of ABIs in nontumor patients with sensorineural hearing loss (SNHL).

We retrospectively reviewed the histories of 15 deaf patients (8 females, 7 males; mean age, 15.5 yr; range, 1-56 yr) who received ABIs for treatment of SNHL at our hospital from July 2008 to November 2015. These included 11 children with narrow internal auditory canals and 4 deaf adults with severe cochlear ossification. In each patient, a 12-channel ABI electrode was placed in the cochlear nucleus complex via a retrosigmoid approach. Auditory performance was evaluated using the Categories of Auditory Performance (CAP) index and sound detection and word identification tests.

One year after ABI placement, 13 of 15 patients showed adequate or significantly improved auditory function based on the CAP scores at the last follow-up. Generally, adult patients tended to show better CAP scores (3.50) than pediatric patients (2.15), but the difference was not significant (P = .058). Postoperative complications included electrode migration, cerebrospinal fluid leakage, nonauditory stimulation, and minor seizures without severe sequelae or mortality.

ABIs show favorable functional outcomes and long-term safety in nontumor deaf patients with limited treatment options. Collectively, our data indicate that ABIs represent an important treatment option for SNHL.